Cancer Anorexia - Epidemiology Forecast - 2036

Cancer Anorexia Insights and Trends

• Cancer anorexia develops very frequently in patients with advanced cancers, such as colorectal cancer, lung cancer, pancreatic cancer, head and neck cancer, gastro-esophageal cancer, and liver cancer.
• Cancer anorexia and Cachexia Syndrome (CACS) is marked by a loss of appetite and weight loss, along with a reduction in muscle mass and fatty tissues, affecting advanced cancer patients with no FDA-approved treatment.
• CACS affects more than 60% of advanced-stage cancer patients.
• Cancer anorexia/cachexia remains significantly underdiagnosed due to the lack of standardized screening protocols and clear diagnostic criteria in routine oncology practice.

DelveInsight's 'Cancer Anorexia - Epidemiology Forecast - 2036' report delivers an in-depth understanding of cancer anorexia, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Cancer Anorexia Understanding and Diagnosis Algorithm

Cancer Anorexia Overview

Cancer anorexia (often part of the broader CACS) is a complex metabolic condition seen in many patients with advanced malignancies. It is characterized by persistent loss of appetite, reduced food intake, weight loss, and progressive muscle wasting that cannot be fully reversed by conventional nutritional support. The condition is driven not only by reduced caloric intake but also by tumor-related inflammation, altered metabolism, and cytokine signaling (such as GDF-15 pathways). It significantly impacts quality of life, reduces tolerance to anticancer therapies, and is associated with poorer survival outcomes.

Cancer Anorexia Diagnosis

Diagnosis is primarily clinical and involves identifying unintentional weight loss (typically >5% over 6 months), decreased appetite, fatigue, and loss of muscle mass. Physicians also assess dietary intake, functional status, and symptoms such as early satiety, nausea, or taste changes. Imaging techniques like CT scans may be used to evaluate muscle mass, while laboratory markers such as inflammatory markers like CRP can support the diagnosis. Importantly, cancer anorexia/cachexia must be differentiated from simple starvation, as metabolic alterations and systemic inflammation play a central role in this condition.

Cancer Anorexia Epidemiology

Key Findings from Cancer Anorexia Epidemiological Analysis and Forecast

• Among the 7MM, the US accounted for the highest number of incident cases of cancer anorexia with ~285,600 cases in 2025.
• Among EU4 and the UK, Germany accounted for the highest number of incident cases of cancer anorexia, while Spain accounted for the fewest incident cases.
• Among all cancer types, lung cancer accounts for the highest incidence of cancer anorexia in the US.
• In 2025, the incident cases of pancreatic cancer were ~67,440, and incident cases of lung cancer were ~226,650 in the US.
• According to secondary analysis, an estimated 72,680 people in the US will be diagnosed with cancer of the oral cavity, pharynx, or larynx, which are the major types of HNC in 2025.
• As per studies, nearly 153,000 new cases of CRC in 2025, with men expected to represent a slightly higher number of cases than women.

Scope of the Report:

• The report covers a segment of a descriptive overview of cancer anorexia, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Cancer Anorexia Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of cancer anorexia? What will be the growth opportunities across the 7MM concerning the patient population with cancer anorexia?
• What is the historical and forecasted cancer anorexia patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.